Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 178, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.addr.2021.113969
Keywords
Targeted delivery; Ovarian cancer; Drug conjugates; Nanomedicine; Drug resistance; Combination therapy
Categories
Funding
- National Natural Science Foundation of China [NSFC 51633005, 51773146, 51861145310]
Ask authors/readers for more resources
Targeted drug delivery systems play a crucial role in enhancing the efficacy of ovarian cancer treatment, improving selectivity, overcoming drug resistance, and reducing toxicity. These systems provide important means to explore innovative treatment modalities.
Ovarian cancer is a high-mortality malignancy in women. The contemporary clinical chemotherapy with classic cytotoxic drugs, targeted molecular inhibitors would mostly fail when ovarian cancer cells become drug-resistant or metastasize through the body or when patients bare no more toleration because of strong adverse effects. The past decade has spotted varying targeted delivery systems including antibody-drug conjugates (ADCs), peptide/folate/aptamer-drug conjugates, polymer-drug conjugates, ligand-functionalized nanomedicines, and dual-targeted nanomedicines that upgrade ovarian cancer chemo-and molecular therapy effectively in preclinical/clinical settings via endowing therapeutic agents selectivity and bypassing drug resistance as well as lessening systemic toxicity. The targeted delivery approaches further provide means to potentiate emergent treatment modalities such as molecular therapy, gene therapy, protein therapy, photodynamic therapy, dual-targeting therapy and combination therapy for ovarian cancer. This review highlights up-to-date development of targeted drug delivery strategies toward advanced, metastatic, relapsed, and drug resistant ovarian cancers. (c) 2021 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available